Fada Medical is developing a novel drug diffusion technology to enhance the wear time and performance of a cannula for long-term insulin pump use in individuals with type 1 diabetes.

Fada Medical

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.

Metric
Company Name	Fada Medical	Simcere Pharmaceutical Group Limited
Symbol		2.10K
MSH ID	COM:FADAMEDICAL	COM:SIMCERE
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Medical Devices	Biotechnology
Country	IE	CN
Stage
Employee Count		7.03K
Website	fadamedical.com	simcere.com
LinkedIn
Founders

Metric
Market Cap		1.85B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		908.88M
Revenue (LTM)
Revenue (NTM)
Gross Profit		685.55M
EBITDA		129.40M
Operating Income		100.74M
Net Income		98.31M
EPS		0.04
Diluted EPS		0.04
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.77
Operating Profit Margin		0.11
EBITDA Margin		0.14
Net Profit Margin		0.45
Return on Equity		0.39
Return on Assets		0.25
Return on Capital Employed		0.09

COM:FADAMEDICAL

Fada Medical

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		13.45
P/B Ratio		1.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.47
EV Multiple		25.52

Metric
Days Sales Outstanding
Days Payables Outstanding		195.23
Days Inventory Outstanding		188.86
Operating Cycle		380.95
Cash Conversion Cycle		285.62
Asset Turnover		0.61

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt		1.09
Operating Cash Flow/Sales		0.17
Free Cash Flow Yield		0.03

Metric
Cash & Equivalents		276.08M
Accounts Receivable
Inventory		84.53M
Goodwill		19.60M
Debt to Capitalization		0.17
Debt to Assets		0.09
Current Ratio		2.35
Quick Ratio		1.93

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.02
R&D to Revenue		0.30
SG&A to Revenue		0.07